Senate "BioShield II" Hearing To Discuss Manufacturer Liability, Development Incentives
This article was originally published in The Pink Sheet Daily
Executive Summary
Joint Health-Judiciary Committee hearing Oct. 6 will review additional incentives for pharmaceutical and biotech firms to develop medical countermeasures for bioterrorism-related threats.
You may also be interested in...
BioShield II Patent Extensions Will Increase Drug Costs, GPhA Says
The Generic Pharmaceuticals Association supports the overall goals of the bill but claims product exclusivity extensions will needlessly inflate pharmaceutical costs. The association will testify before the Oct. 6 joint Senate Judiciary/Health Committee hearing.
BioShield II Patent Extensions Will Increase Drug Costs, GPhA Says
The Generic Pharmaceuticals Association supports the overall goals of the bill but claims product exclusivity extensions will needlessly inflate pharmaceutical costs. The association will testify before the Oct. 6 joint Senate Judiciary/Health Committee hearing.
Senate “BioShield II” Hearing Postponed
The Senate Health Committee will reschedule a hearing on the "Project BioShield II" legislation planned for Sept. 8